Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Bruce Booth
AddedMar 31, 2024
UpdatedMay 31, 2026
Bruce Booth

Bruce Booth

Board Member, Lysosomal Therapeutics

CrunchbaseLinkedIn

Bruce Booth's Career

Lysosomal Therapeutics
Lysosomal Therapeutics

Cambridge, MA, US

Board Member· Board
Kymera Therapeutics
Kymera Therapeutics

Watertown, MA, US

Board Member· Board
Quartet Medicine
Quartet Medicine

Cambridge, MA, US

Board Member· Board
On-Q-ity
On-Q-ity

Waltham, MA, US

Board Member· Board
HotSpot Therapeutics
HotSpot Therapeutics

Boston, MA, US

Board Member· Board
Nimbus Therapeutics
Nimbus Therapeutics

Cambridge, MA, US

Board Member· Board
Matchpoint Therapeutics
Matchpoint Therapeutics

Cambridge, MA, US

Board Member· Board
Arkuda Therapeutics
Arkuda Therapeutics

Watertown, MA, US

Board Member· Board
Sionna Therapeutics
Sionna Therapeutics

Natick, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Bruce Booth's Career

Lysosomal Therapeutics
Lysosomal Therapeutics
Series A$24.8M52011Cambridge, MA, US
Board Member· Board

Leadership at Lysosomal Therapeutics

Clay ThorpClay ThorpBoard Member
Joseph MazzulliJoseph MazzulliCo-Founder
Kees BeenKees BeenCo-Founder
Carole NuechterleinCarole NuechterleinBoard Member
Steve HallSteve HallBoard Member
Edmund SybertzEdmund SybertzCo-Founder
Kymera Therapeutics
Kymera Therapeutics
Public$879M1672017Watertown, MA, US
Board Member· Board

Leadership at Kymera Therapeutics

Donald NicholsonDonald NicholsonBoard Member
Elena RidloffElena RidloffBoard Member
Andrew HedinAndrew HedinBoard Member
Nello MainolfiNello MainolfiCo-Founder
Joanna HorobinJoanna HorobinBoard Member
Jeff AlbersJeff AlbersBoard Member
Quartet Medicine
Quartet Medicine
Series A$23M72013Cambridge, MA, US
Board Member· Board

Leadership at Quartet Medicine

Mark H N CorriganMark H N CorriganBoard Member
John CreecyJohn CreecyBoard Member
Kevin PojasekKevin PojasekFounder
On-Q-ity
On-Q-ity
Series B$31M302009Waltham, MA, US
Board Member· Board

Leadership at On-Q-ity

Dion MadsenDion MadsenBoard Member
Mara AspinallMara AspinallFounder
Dr Robert S Epstein \"Rob\"Dr Robert S Epstein \"Rob\"Board Member

Similar to On-Q-ity

OnCirc DiagnosticsOnCirc DiagnosticsBeverly Hills, CA, USCancer Diagnosticsest. 2009OnCirc DiagnosticsBeverly Hills, CA, US · est. 2009

Innovative cancer diagnostics biotech in Beverly Hills.

Pre-Seed · $500k30
BloodQBloodQOrinda, CA, USCancer Treatment, DiagnosticsBloodQOrinda, CA, US

BloodQ offers personalized cancer treatment through its innovative diagnostic platform analyzing circulating DNA.

Seed · $4.5M2
OncoHealthOncoHealthMountain View, CA, USDiagnostic Testingest. 2009OncoHealthMountain View, CA, US · est. 2009

OncoHealth: Innovating cancer detection with diagnostic testing and screening devices.

Pre-Seed · $3.5M1
OncocyteOncocyteIrvine, CA, USCancer Diagnosticsest. 2009OncocyteIrvine, CA, US · est. 2009

Oncocyte Corporation: A US-based molecular diagnostics firm, optimizing cancer care through accelerated diagnosis and treatment.

Public · $57.2M75
HotSpot Therapeutics
HotSpot Therapeutics
Series C$210M912017Boston, MA, US
Board Member· Board

Leadership at HotSpot Therapeutics

Jo VineyJo VineyBoard Member
Geraldine HarrimanGeraldine HarrimanCo-Founder
Graziano SeghezziGraziano SeghezziBoard Member
Fouad AzzamFouad AzzamBoard Member
Ash KhannaAsh KhannaBoard Member
Henry B. SkinnerHenry B. SkinnerBoard Member

Similar to HotSpot Therapeutics

Bonum TherapeuticsBonum TherapeuticsSeattle, WA, USTherapeuticsest. 2021Bonum TherapeuticsSeattle, WA, US · est. 2021

Bonum Therapeutics: A tech platform innovating treatments for cancer and various diseases.

Series A · $93M27
Atavistik BioAtavistik BioCambridge, MA, USDrug Discoveryest. 2021Atavistik BioCambridge, MA, US · est. 2021

Atavistik Bio: Pioneering pre-clinical biotech firm developing first-in-class drug candidates.

Private Equity · $100M36
Spotlight TherapeuticsSpotlight TherapeuticsHayward, CA, USGene Editing Drugsest. 2017Spotlight TherapeuticsHayward, CA, US · est. 2017

Spotlight Therapeutics: A biotech firm specializing in cell-targeted gene editing drugs.

Series B · $80.7M31
ProFound TherapeuticsProFound TherapeuticsCambridge, MA, USTherapeuticsest. 2022ProFound TherapeuticsCambridge, MA, US · est. 2022

ProFound Therapeutics: Innovating impactful disease understanding and therapeutic creation.

Series A · $75M35
Nimbus Therapeutics
Nimbus Therapeutics
Public$637M1122009Cambridge, MA, US
Board Member· Board

Leadership at Nimbus Therapeutics

Vicki SatoVicki SatoBoard Member
Laura StoppelLaura StoppelBoard Member
Anne McGeorgeAnne McGeorgeBoard Member
Ramy FaridRamy FaridBoard Member
Jeb KeiperJeb KeiperCEO
Daniel LynchDaniel LynchBoard Member

Similar to Nimbus Therapeutics

NGM BiopharmaceuticalsNGM BiopharmaceuticalsSouth San Francisco, CA, USTherapeuticsest. 2007NGM BiopharmaceuticalsSouth San Francisco, CA, US · est. 2007

NGM Biopharmaceuticals: A clinical-stage company developing novel therapeutics for various diseases in the US.

Public · $420.4M225
Nirogy TherapeuticsNirogy TherapeuticsNatick, MA, USDrug Developmentest. 2013Nirogy TherapeuticsNatick, MA, US · est. 2013

Nirogy Therapeutics: Innovating small molecule drugs to target cellular transporters and disrupt tumor growth.

Series A · $18.5M16
Microbiome TherapeuticsMicrobiome TherapeuticsBroomfield, CO, USMedical Researchest. 2009Microbiome TherapeuticsBroomfield, CO, US · est. 2009

Microbiome Therapeutics LLC: A US-based medical research firm specializing in metabolic disease solutions.

Series B · $3M30
Renibus TherapeuticsRenibus TherapeuticsSouthlake, TX, USBiotechest. 2016Renibus TherapeuticsSouthlake, TX, US · est. 2016

Rénibus Therapeutics: A biotech leader in preventing, treating, and diagnosing kidney disease.

Series B · $214.7M200
Matchpoint Therapeutics
Matchpoint Therapeutics
Series A$100M282021Cambridge, MA, US
Board Member· Board

Leadership at Matchpoint Therapeutics

Andre TurenneAndre TurenneCEO

Similar to Matchpoint Therapeutics

Metaphore BiotechnologiesMetaphore BiotechnologiesCambridge, MA, USDrug Discovery, Therapeuticsest. 2021Metaphore BiotechnologiesCambridge, MA, US · est. 2021

Metaphore Biotechnologies: Unveiling revolutionary therapies through biomimicry and machine learning.

Series D · $50M30
Faze MedicinesFaze MedicinesCambridge, MA, USTherapeuticsest. 2020Faze MedicinesCambridge, MA, US · est. 2020

Faze Medicines: A pioneering biotech company specializing in biomolecular condensate therapeutics.

Series A · $81M40
Nested TherapeuticsNested TherapeuticsCambridge, MA, USTherapeuticsest. 2021Nested TherapeuticsCambridge, MA, US · est. 2021

Nested Therapeutics: A biotech innovator designing impactful therapeutics through creative service.

Series A · $125M50
ProFound TherapeuticsProFound TherapeuticsCambridge, MA, USTherapeuticsest. 2022ProFound TherapeuticsCambridge, MA, US · est. 2022

ProFound Therapeutics: Innovating impactful disease understanding and therapeutic creation.

Series A · $75M35
Arkuda Therapeutics
Arkuda Therapeutics
Series B$108M302018Watertown, MA, US
Board Member· Board

Leadership at Arkuda Therapeutics

Gerhard KoenigGerhard KoenigFounder
Johannes FruehaufJohannes FruehaufBoard Member

Similar to Arkuda Therapeutics

Lysosomal TherapeuticsLysosomal TherapeuticsCambridge, MA, USDrug Developmentest. 2011Lysosomal TherapeuticsCambridge, MA, US · est. 2011

US-based Lysosomal Therapeutics Inc innovates in neurodegeneration research, developing treatments for severe neurological diseases.

Series A · $24.8M5
Denali TherapeuticsDenali TherapeuticsSan Francisco, CA, USBiotechest. 2015Denali TherapeuticsSan Francisco, CA, US · est. 2015

Denali Therapeutics, a US-based biotech firm, develops medicines for neurodegenerative diseases.

Public · $622M427
Endlyz TherapeuticsEndlyz TherapeuticsBoston, MA, USTherapeuticsest. 2021Endlyz TherapeuticsBoston, MA, US · est. 2021

Boston-based medical organization developing therapeutics for neurodegenerative diseases.

Angel · $3.3M50
Aprinoia TherapeuticsAprinoia TherapeuticsCambridge, MA, USDiagnostic Tools, Therapiesest. 2015Aprinoia TherapeuticsCambridge, MA, US · est. 2015

APRINOIA: A global biotech leader in precision neuroscience, innovating diagnostic tools and therapies for neurodegenerative diseases.

Series A · $61.9M75
Sionna Therapeutics
Sionna Therapeutics
Series B$110M332019Natick, MA, US
Board Member· Board

Leadership at Sionna Therapeutics

Greg HurlbutGreg HurlbutCo-Founder
Mark MunsonMark MunsonCo-Founder
Mark M.Mark M.Co-Founder
Deborah Grey PmpDeborah Grey PmpCEO

Similar to Sionna Therapeutics

SynspiraSynspiraFramingham, MA, USBiotechest. 2017SynspiraFramingham, MA, US · est. 2017

Synspira Therapeutics: A clinical-stage biotech firm innovating treatments for cystic fibrosis and rare diseases.

Series B · $25.2M8
Santi TherapeuticsSanti TherapeuticsBoston, MA, USTherapeuticsest. 2019Santi TherapeuticsBoston, MA, US · est. 2019

Boston-based medical research company developing small molecule therapeutics since 2019.

Series A · $16M30
Synnovation TherapeuticsSynnovation TherapeuticsWilmington, DE, USOncology Therapiesest. 2021Synnovation TherapeuticsWilmington, DE, US · est. 2021

Synnovation Therapeutics: Precision oncology firm specializing in small molecule therapies for cancer.

Series A · $139M18
Nested TherapeuticsNested TherapeuticsCambridge, MA, USTherapeuticsest. 2021Nested TherapeuticsCambridge, MA, US · est. 2021

Nested Therapeutics: A biotech innovator designing impactful therapeutics through creative service.

Series A · $125M50

Bruce Booth's Similar Executives & Operators

Nugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance Retail

People Similar to Bruce Booth

Freda Lewis-HallFreda Lewis-HallBoard Member · Patient-Centered Outcomes Research Institute - PcoriWayne J. RileyWayne J. RileyBoard Member · HCA HealthcarePhilip OzuahPhilip OzuahCEO · Montefiore Medical CenterMarvin FriedMarvin FriedBoard Member · Montefiore Medical CenterJohn D. WrenJohn D. WrenBoard Member · OmnicomSteven M. SafyerSteven M. SafyerBoard Member · Montefiore Medical Center